No Data
Jinling Pharmaceutical: 2024 Annual Report
Jinling Pharmaceutical: 2024 Annual Report Summary
Jinling Pharmaceutical (000919.SZ) released its performance for 2024, with a net income of 40.4098 million yuan, a decrease of 61.95%.
Jinling Pharmaceutical (000919.SZ) released its 2024 annual report, with the company's revenue amounting to 3.281 billion...
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Jinling Pharmaceutical (000919.SZ): has noted the impact of AI applications on the pharmaceutical Industry and will study relevant possible applications according to needs and industry development conditions.
Gelonghui, February 24th丨Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company has paid attention to the impact of AI applications on the pharmaceutical Industry and will study relevant possible applications as needed and according to the development status of the Industry.
Jinling Pharmaceutical (000919.SZ): Currently, there is no relevant data on Assets.
Gelonghui reported on February 20 that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company currently has no relevant data assets.
Investors One-year Losses Continue as Jinling Pharmaceutical (SZSE:000919) Dips a Further 10% This Week, Earnings Continue to Decline
